Processing math: 100%
Review

Anti-HIV lectins and current delivery strategies

  • Lectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereby preventing viral entry and replication processes. Several natural lectins extracted from plant, fungi, algae, bacteria and animals, as well as boronic acid-based synthetic lectins, have been investigated against the Human Immunodeficiency Virus (HIV). This manuscript discusses the nature of HIV envelope glycoprotein glycans and their implication in lectin antiviral activity for HIV/AIDS prevention. In addition, anti-HIV lectins and their carbohydrate specificity is reported. Furthermore, current formulations of anti-HIV lectins are presented to illustrate how to overcome delivery challenges. Although antiviral lectins will continue to occupy a major stage in future microbicide research, further investigation in this field should focus on novel delivery strategies and the clinical translation of CBAs.

    Citation: Fohona S. Coulibaly, Danielle N. Thomas, Bi-Botti C. Youan. Anti-HIV lectins and current delivery strategies[J]. AIMS Molecular Science, 2018, 5(1): 96-116. doi: 10.3934/molsci.2018.1.96

    Related Papers:

    [1] Samuel Kwaku Agyei, Ahmed Bossman . Investor sentiment and the interdependence structure of GIIPS stock market returns: A multiscale approach. Quantitative Finance and Economics, 2023, 7(1): 87-116. doi: 10.3934/QFE.2023005
    [2] Elvira Caloiero, Massimo Guidolin . Volatility as an Alternative Asset Class: Does It Improve Portfolio Performance?. Quantitative Finance and Economics, 2017, 1(4): 334-362. doi: 10.3934/QFE.2017.4.334
    [3] Rubaiyat Ahsan Bhuiyan, Tanusree Chakravarty Mukherjee, Kazi Md Tarique, Changyong Zhang . Hedge asset for stock markets: Cryptocurrency, Cryptocurrency Volatility Index (CVI) or Commodity. Quantitative Finance and Economics, 2025, 9(1): 131-166. doi: 10.3934/QFE.2025005
    [4] Mehmet F. Dicle, John D. Levendis . Hedging Market Volatility with Gold. Quantitative Finance and Economics, 2017, 1(3): 253-271. doi: 10.3934/QFE.2017.3.253
    [5] Mehmet F. Dicle . US Implied Volatility as A predictor of International Returns. Quantitative Finance and Economics, 2017, 1(4): 388-402. doi: 10.3934/QFE.2017.4.388
    [6] Wenhui Li, Normaziah Mohd Nor, Hisham M, Feng Min . Volatility conditions and the weekend effect of long-short anomalies: Evidence from the US stock market. Quantitative Finance and Economics, 2023, 7(2): 337-355. doi: 10.3934/QFE.2023016
    [7] Hammad Siddiqi . Financial market disruption and investor awareness: the case of implied volatility skew. Quantitative Finance and Economics, 2022, 6(3): 505-517. doi: 10.3934/QFE.2022021
    [8] Emmanuel Assifuah-Nunoo, Peterson Owusu Junior, Anokye Mohammed Adam, Ahmed Bossman . Assessing the safe haven properties of oil in African stock markets amid the COVID-19 pandemic: a quantile regression analysis. Quantitative Finance and Economics, 2022, 6(2): 244-269. doi: 10.3934/QFE.2022011
    [9] Xiaohang Ren, Weixi Xu, Kun Duan . Fourier transform based LSTM stock prediction model under oil shocks. Quantitative Finance and Economics, 2022, 6(2): 342-358. doi: 10.3934/QFE.2022015
    [10] Mustafa Tevfik Kartal . The behavior of Sovereign Credit Default Swaps (CDS) spread: evidence from Turkey with the effect of Covid-19 pandemic. Quantitative Finance and Economics, 2020, 4(3): 489-502. doi: 10.3934/QFE.2020022
  • Lectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereby preventing viral entry and replication processes. Several natural lectins extracted from plant, fungi, algae, bacteria and animals, as well as boronic acid-based synthetic lectins, have been investigated against the Human Immunodeficiency Virus (HIV). This manuscript discusses the nature of HIV envelope glycoprotein glycans and their implication in lectin antiviral activity for HIV/AIDS prevention. In addition, anti-HIV lectins and their carbohydrate specificity is reported. Furthermore, current formulations of anti-HIV lectins are presented to illustrate how to overcome delivery challenges. Although antiviral lectins will continue to occupy a major stage in future microbicide research, further investigation in this field should focus on novel delivery strategies and the clinical translation of CBAs.


    1. Introduction

    Undoubtedly, there are extremely more 'bad' than 'good' news during the bear market periods. Nelson (1991) points out that researchers beginning with Black (1976) have found the evidence that stock returns are negatively correlated with changes in returns volatility, i.e. volatility tends to rise in response to 'bad news' (excess returns lower than expected) and to fall in response to 'good news' (excess returns higher than expected).

    The purpose of this paper is to investigate the asymmetric impact of innovations on volatility in the case of three largest European stock markets in the UK, France and Germany, using univariate EGARCH approach (Nelson, 1991). We try to deal with the 'nonsynchronous trading effect Ⅱ' (Olbrys, 2013a) by using a 'common trading window' procedure and estimating suitable EGARCH models based on daily percentage logarithmic returns for the major European stock market indexes: FTSE100 (London), CAC40 (Paris) and DAX (Frankfurt). The main goal is to obtain an overlapping information set in the case of all markets, as we plan to test the impact of common 'bad' and 'good' news. We compare empirical results for the whole sample period from January 2,2003 to December 30,2016 and three adjacent subsamples, each of equal size: 1) the pre-crisis, 2) the Global Financial Crisis (GFC) and 3) the post-crisis periods. The impact of 'bad' and 'good' news is described in terms of univariate EGARCH models. We observe pronounced negative asymmetry effects in the case of all investigated markets and the results turn out to be robust to the choice of the period.

    The remainder of the study is organized as follows. Section 2 specifies a methodological background and a brief literature review. First, we stress the validity of nonsynchronous trading problems. Next, we use a formal statistical procedure of dividing market states into bullish and bearish markets to detect 'down market' (crisis) periods in the analyzed countries. A brief theoretical framework concerning EGARCH (p, q) models is also presented. In Section 3, we describe the data and discuss empirical results of the asymmetric impact of innovations on volatility in the group of investigated markets. Conclusion recalls the main findings and sums them up.


    2. Methodological Background


    2.1. The nonsynchronous trading problem

    According to the literature, one can distinguish between two nonsynchronous trading effect problems (Olbrys, 2013a). The first problem, called 'nonsynchronous trading effect Ⅰ', occurs when we analyze one selected domestic stock market. Stock tradings do not occur in a synchronous manner. Different stocks have different trading frequencies and even for a single stock the trading intensity varies from hour to hour and from day to day. The actual time of last transaction of the stock varies from day to day. As such we incorrectly assume daily returns as an equally spaced time series with a 24-hour interval (Tsay, 2010). The non-trading effect induces potentially serious biases in the moments and co-moments of asset returns such as their means, variances, covariances, betas, autocorrelation and cross-autocorrelation coefficients (Campbell et al., 1997). The second and potentially serious problem, called 'nonsynchronous trading effect Ⅱ', occurs when we examine the relations between stock markets in various countries. The national stock markets are operating in diverse time zones with different opening and closing times, thereby making return observations nonsynchronous (Eun and Shim, 1989; Olbrys, 2013a). These differences arise naturally from the fact that trading days in different countries are subject to different national and religious holidays, unexpected events and so forth (Baumöhl and Výrost, 2010).

    In this paper, we investigate the asymmetric impact of innovations on volatility in the case of three largest European stock markets in the UK, France and Germany. Therefore, we have to deal with the 'nonsynchronous trading effect Ⅱ'. Many studies attempted various methods to deal with this problem. Some researchers use weekly or monthly data to avoid the non-trading effect. Such solutions, however, may lead to small sample sizes and cannot capture the information transmission in shorter (daily) timeframes (Baumöhl and Výrost, 2010). Other papers present various daily data-matching procedures. We employ the following approach, also called a 'common trading window': the data are collected for the same dates across the stock markets, removing the data for those dates when any series has a missing value due to no trading (Eun and Shim, 1989; Booth et al., 1997; Olbrys, 2013a; Olbrys and Majewska, 2014b). It is important to note that the use of a wide range of time-series models could be questionable if non-synchronicities are not accounted for, especially because the current implementations of these models in most econometric software inherently assume synchronous data.


    2.2. Direct identification of crisis periods on the major European stock markets

    Direct quantitative identification of crisis periods is possible based on statistical procedures of dividing market states into bullish and bearish markets. Fabozzi and Francis (1977) stress that no just one definition of bull and bear markets exists. Therefore, they proposed three alternative definitions of bull and bear market conditions. The first categorization was based on market trends. The second partitioning procedure ignored market trends and viewed the market portfolio return every month independently. The third procedure partitioned the sample into three subsets: (1) months when the market moved up substantially, (2) months when the market moved down substantially and (3) months when the market moved neither up nor down substantially. Substantial moves were arbitrarily defined as months when the absolute value of market return was larger than half of one standard deviation of the market returns measured over the total sampled period (Fabozzi and Francis, 1977).

    Pagan and Sossounov (2003) developed an algorithm that seemed to be successful in locating periods in time that were considered bull and bear markets in U.S. equity prices. They tested monthly data of the New York market index-S & P500, in the period from January 1835 to May 1997. Lee et al. (2011) use a modified version of the Pagan and Sossounov (2003) method of dividing market states into bullish and bearish markets. They analyze the Taiwanese market, in the period from January 1997 to December 2007. Lee et al. (2011) point out that investors usually cannot identify the present market state and they often refer to past market states as they make investment decisions.

    We employ a three-stage procedure of dividing market states into up and down markets. Our methodology builds on Pagan and Sossounov (2003). In the first step, we conduct a preliminary identification of turning points, i.e., peaks and troughs, based on the conditions (1)–(2), respectively:

    $ \ln {P_{t - 8}}, \ldots ,\ln {P_{t - 1}} < \ln {P_t} > \ln {P_{t + 1}}, \ldots ,\ln {P_{t + 8}} $ (1)
    $ \ln {P_{t - 8}}, \ldots ,\ln {P_{t - 1}} > \ln {P_t} < \ln {P_{t + 1}}, \ldots ,\ln {P_{t + 8}} $ (2)

    where Pt represents the market index of month t, and from successive peaks/troughs we choose the highest/deepest one, respectively. Pagan and Sossounov (2003) stress that in the business cycle literature an algorithm for describing turning points in time series was developed by Bry and Boschan (1971), but they modified this algorithm by taking the eight months window (instead of six) in marking the initial location of turning points. The main goal was not to smooth any of the monthly, already smoothed, data. In the second step, we rule out the phases (peak-trough or trough-peak) that last for less than four months and cycles (peak-trough-peak or trough-peak-trough) that last for less than sixteen months. Pagan and Sossounov (2003) point out that in business cycle dating the minimal cycle length is fifteen months, hence sixteen months were chosen to create a symmetric window of eight periods. Moreover, they advocated four months as the minimal length of a phase.

    In the last step we calculate the amplitudes A for each phase (amplitude is the difference in the natural logs of the index value in subsequent turning points). During the bull/bear market period there must be a large enough (of at least 20%) rise/fall in the index value (Pagan and Sossounov, 2003). This means that the amplitude of a given phase must fulfill the condition A ≥ 0.18 or A ≤ -0.22 for the bull or bear market period, respectively. Indeed, if a growth of the index value in an up market period will equal at least to 20%, then (Olbrys and Majewska, 2014a):

    $ A =\ln {P_{t + 1}} - \ln {P_t} =\ln \frac{{{P_{t + 1}}}}{{{P_t}}} > \ln \frac{{1.2 \cdot {P_t}}}{{{P_t}}} =\ln 1.2 \approx 0.18 $ (3)

    By analogy, if a decline of the index value in a down market period will equal at least to 20%, then:

    $ A =\ln {P_{t + 1}} - \ln {P_t} =\ln \frac{{{P_{t + 1}}}}{{{P_t}}} < \ln \frac{{0.8 \cdot {P_t}}}{{{P_t}}} =\ln 0.8 \approx - 0.22 $ (4)

    The data consists of monthly logarithmic returns of three major developed European stock market indexes: FTSE100, CAC40 and DAX. Figures 13 present down market periods for the market indexes obtained from the procedure described above, in the whole sample from January 2003 to December 2016. The horizontal axis stands for time (months), and the vertical axis stands for the market index. Vertical lines and light grey areas stand for down market periods.

    Figure 1. October 31,2007—February 27,2009 as the GFC period for FTSE100 (London).
    Source: Authors' calculations.
    Figure 2. May 31,2007—February 27,2009 as the GFC period for CAC40 (Paris).
    Source: Authors' calculations.
    Figure 3. December 28,2007—February 27,2009 as the GFC period for DAX (Frankfurt).
    Source: Authors' calculations.

    The obtained results reveal that October 2007—February 2009 was the Global Financial Crisis (GFC) period for the stock market in London. The GFC period for the Paris stock exchange was longer and it lasted from May 2007 to February 2009, while the crisis period for the Frankfurt stock market was shorter and it lasted from December 2007 to February 2009. Our results confirm February 2009 as the end of down markets in all investigated countries (Olbrys and Majewska, 2014a). The precise identification of market states is certainly important in practice, as many researchers found that profits to investment strategies depend critically on the state of the market. Moreover, it is instructive to formally identify crises, as it enables the examination of various relationships among international stock markets, taking into consideration the pre-, post-and crisis periods (Olbryś and Majewska, 2015).


    2.3. The exponential GARCH model

    Many researchers documented that stock return volatility tends to rise following 'good' and 'bad' news. This phenomenon was noted both for individual stocks and for market indexes (Braun et al., 1995). Since Nelson (1991) introduced the univariate Exponential Generalized Autoregressive Conditionally Heteroskedastic (EGARCH) model, some researchers employ this model to capture the asymmetric effect of innovations on volatility. Engle and Ng (1993) stress that the main advantage of EGARCH model is that it allows 'good' news and 'bad' news to have a different impact on volatility, while the standard GARCH model does not.

    Several studies present various applications of univariate and multivariate EGARCH models. Koutmos and Booth (1995) investigate the transmission mechanism of price and volatility spillovers across the New York, Tokyo and London stock markets from three different time zones, using the EGARCH approach. Jane and Ding (2009) propose the multivariate extension of Nelson's univariate EGARCH model and compare their model with the existing one given by Koutmos and Booth (1995). Booth et al. (1997) provide the evidence on price and volatility spillovers among four Scandinavian (Nordic) stock markets. Bhar (2001) applies an extended bivariate EGARCH model to provide evidence of linkages between the equity market and the index futures market in Australia. Reyes (2001) examines volatility transfers between size–based indexes from the Tokyo Stock Exchange, using a bivariate EGARCH model. Tse et al. (2003) employ a bivariate EGARCH model that allows for both mean and variance spillovers between the US and Polish stock markets. Yang and Doong (2004) adopt a bivariate EGARCH framework to investigate price and volatility spillovers between stock prices and exchange rates in the group of the G-7 countries. Balaban and Bayar (2005) test the relationship between stock market returns and their forecast volatility derived from the symmetric and asymmetric GARCH-type models in 14 countries. Bhar and Nikolova (2009) investigate the level of integration and the dynamic relationship between the BRIC countries (i.e. Brazil, Russia, India and China) using bivariate EGARCH framework. Curto et al. (2009) employ the MSV-EGARCH specification to explore links between stock market returns, volatility and treading volume in the case of six major international stock market indexes. Lee and Stewart (2010) examine asymmetric effects on volatility in the case of the Baltic and Nordic major stock indexes, using both univariate and multivariate EGARCH models. Olbrys (2013a) investigates the interdependence of price volatility across the US developed stock market and two emerging Central and Eastern European (CEE) markets in Warsaw and Budapest using a multivariate modified EGARCH model. Abbas et al. (2013) analyze volatility transmission from one market to another in the case of selected Asian stock markets in Pakistan, China, Sri Lanka and India, as well as developed equity markets in the US, UK, Japan and Singapore. The authors employ bivariate EGARCH model and results show that volatility transmission is present especially between friendly countries in different regions with economic links. Kuttu (2014) uses MVAR-EGARCH model to examine the return and volatility dynamics between thin-traded adjusted equity returns from Ghana, Kenya, Nigeria, and South Africa. Dedi and Yavas (2016) explore linkages between equity market returns and volatility spillovers in the UK, Germany, China, Russia, and Turkey. They apply EGARCH model among various GARCH methodologies.

    The asymmetric effects of innovations on volatility for one selected domestic stock market could be well described by the univariate EGARCH model (Olbryś, 2013b) although it is now widely accepted that a multivariate modeling framework (in the case of the group of markets) leads to more relevant empirical models than working with separate univariate models (Bauwens et al., 2006). But it is worth stressing that a multivariate EGARCH model estimation is particularly difficult due to the large number of estimated parameters, especially when we use a sample of a relatively small size.

    The univariate time series $\{ {R_t}\} $ can be expressed as:

    $ {R_t} ={\mu _t} + {\varepsilon _t}, $ (5)

    where: ${\sigma _t} =Var({R_t}\left| {{F_{t -1}})} \right.$ is the conditional expectation of ${R_t}$ given the past information ${F_{t -1}}$, ${\varepsilon _t}$ is the innovation of the series at time t.

    Nelson's univariate EGARCH (p, q) model can be represented as follows (Tsay, 2010):

    $ ln(σ2t)=α0+1+β1B++βq1Bq11α1BαpBpg(zt1),εt=σtzt,εt|Ft1N(0,σt),ztN(0,1)
    $
    (6)
    $ g({z_t}) =\theta \cdot {z_t} + \gamma \cdot {\rm{[}}\left| {{z_t}} \right| - E(\left| {{z_t}} \right|){\rm{]}}, $ (7)

    where: ${\sigma _t} =Var({R_t}\left| {{F_{t -1}})} \right.$ is the conditional variance of ${R_t}$ given the past information ${F_{t -1}}$, ${\alpha _0}$ is a constant, B is the back-shift (or lag) operator such that $Bg({z_t}) =g({z_{t -1}})$, $1 + {\beta _1}B + \cdots + {\beta _{q -1}}{B^{q -1}}$ and $1 -{\alpha _1}B -\cdots -{\alpha _p}{B^p}$ are polynomials with zeros outside the unit circle and have no common factors.

    The value of $g({z_t})$ depends on several elements. Nelson (1991) points out that to accommodate the asymmetric relation between stock returns and volatility changes, the value of $g({z_t})$ must be a function of both the magnitude and the sign of ${z_t}$. In Eq. (7), $g({z_t})$ is a linear combination of ${z_t}$ and $[\left| {{z_t}} \right| -E(\left| {{z_t}} \right|)]$ with coefficients $\theta $ and $\gamma $. The term in the bracket measures the magnitude effects and the coefficient $\gamma $ relates lagged standardized innovations to volatility in a symmetric way. The term $\theta \cdot {z_t}$ measures the sign effects and the coefficient $\theta $ relates standardized shocks to volatility in an asymmetric style. ${\{ g({z_t})\} _{t =-\infty, \infty }}$ is an i.i.d. random sequence with mean zero (Jane and Ding 2009). For $\theta < 0$ the future conditional variances will increase proportionally more as a result of a negative shock than for a positive shock of the same absolute magnitude (Bollerslev and Mikkelsen 1996). Both ${z_t}$ and $[\left| {{z_t}} \right| -E(\left| {{z_t}} \right|)]$ are zero mean i.i.d. random sequences with continuous distributions. The asymmetry of $g({z_t})$ can be easily seen by rewriting it as:

    $ g({z_t}) =\left\{ {(θ+γ)ztγE(|zt|)ifzt0,(θγ)ztγE(|zt|)ifzt<0.
    } \right. $
    (8)

    Since EGARCH (p, q) =EGARCH(1, 1) is a simple case, Eq. (6) becomes:

    $ (1 - {\alpha _1}B) \cdot \ln (\sigma _t^2) =(1 - {\alpha _1}B) \cdot {\alpha _0} + g({z_{t - 1}}), $ (9)

    Eq. (9) can be rewritten (subscript of ${\alpha _1}$ is omitted) and then:

    $ \ln (\sigma _t^2) =\alpha _0^* + \alpha \cdot \ln (\sigma _{t - 1}^2) + g({z_{t - 1}}), $ (10)

    where $\alpha _0^* =const$.

    The parameter α in Eq. (10) determines the influence of the past conditional volatility on the current conditional volatility. For the conditional volatility process to be stationary, $\left| \alpha \right| < 1$ is required. The persistence of volatility may be also quantified by examination of the half–life (HL) defined by:

    $ HL =\frac{{\ln (0.5)}}{{\ln \left| \alpha \right|}} $ (11)

    which measures the time period required for the innovations to be reduced to one–half of their original size.

    Let ${R_{i, t}}$ be the percentage logarithmic return at time t for market i (i = 1, 2, 3, where 1 = London, 2 = Paris, and 3 = Frankfurt). Then, the univariate AR (1)–EGARCH (1, 1) model for market i may be written as follows:

    $ Ri,t=ϕi,0+ϕiRi,t1+εi,t,ln(σ2i,t)=αi,0+αiln(σ2i,t1)+θizt+γi[|zt|E(|zt|)].
    $
    (12)

    3. Empirical Results


    3.1. Data description and preliminary statistics

    The data consists of daily percentage logarithmic returns for major stock market indexes for London (FTSE100 index), Paris (CAC40 index), and Frankfurt (DAX index). As mentioned in Introduction, the goal was to obtain the overlapping information set in the case of all markets, as we planned to test the impact of common 'bad' and 'good' news. We used the 'common trading window' procedure and removed the data for those dates when any series has a missing value due to no trading (Olbrys and Majewska, 2014b). Thus all the data are collected for the same dates across three markets and finally there are 3509 observations for each series for the period beginning January 2,2003 and ending December 30,2016. It is worth stressing that the reduction in the number of observations is not substantial, as the group of markets is small (Olbrys and Majewska, 2014b). Table 1 reports summarized statistics for daily percentage logarithmic returns for three stock indexes (in order of decreasing value of market capitalization at the end of 2015), as well as statistics testing for normality and interdependence.

    Several results in Table 1 are worth special notice. The sample means are not statistically different from zero. The measure for skewness shows that the FTSE100 return series is negatively and significantly skewed, while the measure for excess kurtosis shows that all return series and highly leptokurtic with respect to the normal distribution. The Doornik-Hansen (2008) test rejects normality for each of the return series at the 5 per cent level of significance. The Ljung-Box (1978) statistic at the lag q≈lnT, where T is the number of data points (Tsay, 2010), calculated for both the return and the squared return series, indicates the presence of significant linear and non-linear dependencies, respectively. The linear dependences may be due to the 'nonsynchronous trading effect Ⅰ' of the stocks that make up each index (Campbell et al., 1997). The non–linear dependences may be due to the autoregressive conditional heteroskedasticity (Nelson, 1991; Koutmos and Booth, 1995; Booth et al., 1997). Calculations have been conducted using the open-source computer software Gretl 1.10.1 (Adkins, 2014).

    Table 1. Summarized statistics for daily percentage logarithmic returns for three stock indexes: FTSE100 (London), CAC40 (Paris), and DAX (Frankfurt).
    Index Market Cap. EUR Billion, Dec 2015 Mean St. Dev. Skewness Excess kurtosis Doornik-Hansen test LB(8) LB2(8)
    1 FTSE100 3009.5 0.017 1.169 -0.119 [0.004] 7.722 [0.000] 2547.86 [0.000] 46.81 2020.92
    2 CAC40 1911.2 0.014 1.432 -0.009 [0.822] 5.909 [0.000] 1803.01 [0.000] 37.20 1234.00
    3 DAX 1781.6 0.039 1.428 -0.015 [0.714] 5.239 [0.000] 1529.57 [0.000] 18.54 1102.94
    Source: Authors' calculations and http://sdw.ecb.europa.eu.
    Notes: The table is based on all sample observations during the period January 2,2003–December 30,2016. The test statistic for skewness and excess kurtosis is the conventional t-statistic. The Doornik-Hansen test (2008) has a χ2 distribution if the null hypothesis of normality is true. Numbers in brackets are p-values. LB (q) and LB2(q) are the Ljung-Box (1978) statistics for returns and squared returns, respectively, distributed as χ2(q), q≈lnT, where T is the number of data points (Tsay, 2010). The χ2(8) critical value is equal to 15.51 (5%).
     | Show Table
    DownLoad: CSV

    3.2. Asymmetric impact of innovations on volatility on the major European stock markets

    To examine asymmetric effects between positive and negative index return innovations, we first estimate the univariate AR (1)–EGARCH (1, 1) models of three stock indexes: FTSE100 (London), CAC40 (Paris) and DAX (Frankfurt), in the whole sample period from January 2,2003 to December 30,2016. The robust QML (Bollerslev and Wooldridge, 1992) estimates of the parameters of the model (12) are presented in Table 2.

    Table 2. Results from the AR (1)–EGARCH (1, 1) models of three stock indexes: FTSE100, CAC40, and DAX, in the whole sample period from January 2,2003 to December 30,2016 (3509 daily observations).
    London (i=1) Paris (i=2) Frankfurt (i=3)
    The distribution for the innovations (the best fitted model) skewed t skewed t skewed t
    Conditional mean equation
    ${\varphi _{i, 0}}$ 0.006 (0.013) 0.007 (0.017) 0.035 (0.019)
    ${\varphi _i}$ -0.040* (0.017) -0.051* (0.016) -0.014 (0.025)
    Conditional variance equation
    $\alpha _{i, 0}^*$ -0.103* (0.015) -0.072* (0.010) -0.089* (0.010)
    ${\alpha _i}$ 0.981* (0.004) 0.977* (0.005) 0.979* (0.004)
    ${\theta _i}$ -0.142* (0.014) -0.163* (0.017) -0.135* (0.016)
    ${\gamma _i}$ 0.129* (0.018) 0.102* (0.014) 0.125* (0.014)
    Conditional density parameters
    ${\nu _i}$ 13.568* (2.735) 10.380* (1.715) 9.219* (1.428)
    ${\lambda _i}$ -0.151* (0.023) -0.138* (0.024) -0.133* (0.021)
    Asymmetry effect for market i
    ${\delta _i} = {\theta _i}/\gamma $ -1.10 < 0 -1.60 < 0 -1.08 < 0
    Half–life (HL) 36.13 29.79 32.66
    Log–likelihood -4659.73 -5503.42 -5544.81
    LB(20) 11.55 [0.93] 23.12 [0.28] 20.58 [0.42]
    LB2(20) 26.13 [0.16] 7.84 [0.99] 15.35 [0.76]
    Source: Authors' calculations
    Notes: * denotes significance at the 5 per cent level. The heteroskedastic consistent standard errors are in parentheses. The variance-covariance matrix of the estimated parameters is based on the QML algorithm. The distribution for the innovations is supposed to be skewed t; ν and λ are conditional density parameters (Lucchetti and Balietti, 2011). The asymmetry coefficient is defined in the text. The half-life is defined in the text and represents the time it takes for the shock to reduce its impact by one-half. LB (20) and LB2(20) denotes the Ljung-Box (1978) statistics for standardized innovations and squared standardized innovations, respectively (Baillie and Bollerslev, 1990). Numbers in brackets are p-values.
     | Show Table
    DownLoad: CSV

    In the case of all analyzed periods, the choice of an appropriate version of the EGARCH model was conducted based on the BIC and AIC information criterions, and distributions for the innovations were supposed to be normal, t-Student, or skewed t. As it turned out, the univariate AR (1)–EGARCH (1, 1) models with skewed t as the distribution for the innovations are the most adequate for all series in the whole sample period. Calculations concerning EGARCH models have been done using GAUSS package with FANPAC MT 3.0 module.

    For model checking, the Ljung-Box statistics LB (20) for the standardized innovation process and LB2(20) for the squared standardized innovations have been applied (Baillie and Bollerslev, 1990). The evidence is that there is no serial correlation or conditional heteroskedasticity in the standardized innovations of the fitted models in the whole sample period. Therefore we can conclude that the estimated AR (1)–EGARCH (1, 1) models are adequate (Tsay, 2010).

    Several results presented in Table 2 are worth a comment. The autoregressive coefficients φi are negative and statistically significant for the London and Paris markets. The conditional variance is a function of past conditional variances and past innovations. The relevant coefficients αi, θi and γi are statistically significant at the 5 per cent level in the case of all models. In addition, all of the γicoefficients are positive. For positive γi, if δii/ γi < 0, then negative innovations have a higher impact on volatility than positive innovations. If δi = 0 (θi = 0 and γi > 0), then the magnitude terms raises (lowers) volatility when the magnitude of market movements is large (small). If 0 < δi < 1, then positive innovations would increase volatility but negative innovations decrease volatility. These pronounced negative asymmetry effects are present in Table 2. For London, Paris, and Frankfurt, negative innovations increase volatility considerably more than positive innovations. Our findings suggest that the investigated stock markets are more sensitive to 'bad' than 'good' news.

    The persistence of volatility may be interpreted by using the half-life concept (11), which measures the time it takes for an innovation to reduce its impact by one half. Numerically, the HL coefficients for the London, Paris, and Frankfurt indexes are equal to: 36.13, 29.79 and 32.66 days, respectively. It is worth stressing that the half–life coefficients are rather high, however Olbryś (2013b) documents that half–life coefficients for the New York, Warsaw, Prague, and Budapest indexes are equal to: 31.16, 40.43, 29.79, and 32.66 days, respectively. Moreover, Scheicher (2001) documents half–life coefficients for the CTX, HTX, and PTX indexes, which are equal to: 16.39, 1.95, and ∞ (!) days. Bhar (2001) reports half–life coefficients equal to 2.63 and 3.86 days for two Australian spot and futures markets.

    Subsequent Tables 35 present details concerning further numerical results from the AR(1)–EGARCH(1, 1) models of three stock indexes in three adjacent subsamples, each of equal size: (1) the pre-GFC (Table 3), (2) the GFC (Table 4) and (3) the post-GFC (Table 5) periods, respectively. As mentioned in subsection 2.2, we have obtained different GFC periods for analyzed stock markets (see Figures 13), hence the corresponding adjacent subperiods are different as well.

    The results in Tables 35 reveal that the asymmetric effects between positive and negative index return innovations are presented for all markets and turn out to be robust to the choice of the period. Almost all of the γi coefficients are significantly positive and almost all of the θi coefficients are significantly negative (at the 5 percent level). Hence, the corresponding δii/γi coefficients are negative, except for the DAX index during the post-GFC period, which is reported in Table 5. However, the DAX best fitted EGARCH model is qualitatively rather poor. Therefore, we can conclude that negative innovations have a higher impact on the volatility than positive innovations. This evidence confirms that the investigated European stock markets are more sensitive to 'bad' than 'good' news, regardless of the subperiod choice. The half-life coefficients (11), which measure the persistence of volatility for the London, Paris, and Frankfurt indexes during the pre-, crisis and post-crisis periods are equal to: (1) 16.98, 12.98 and 8.54 days (for the pre-GFC period – Table 3), (2) 22.76, 23.55 and 24.40 days (for the GFC period–Table 4) and (3) 16.15, 10.48 and 692.80 days (for the post-GFC period–Table 5), respectively. However, as mentioned, the quality of the best fitted EGARCH model for the Frankfurt Stock Exchange is rather low (for details see Table 5). Excluding the DAX index, the results for FTSE100 and CAC40 indexes during the pre-and post-GFC periods are quantitatively almost the same, while during the GFC period the HL values, which inform about time required for innovations to be reduced to one–half of their original size, are slightly higher for all stock markets.

    Table 3. Results from the AR (1)–EGARCH (1, 1) models of three stock indexes: FTSE100, CAC40, and DAX, in the pre-GFC period.
    London (i=1) Paris (i=2) Frankfurt (i=3)
    Pre-GFC period 11.07.2006–30.10.2007 331 daily observations 1.09.2005–30.05.2007 439 daily observations 30.10.2006–27.12.2007 292 daily observations
    The distribution for the innovations (the best fitted model) normal t-Student skewed t
    Conditional mean equation
    ${\varphi _{i, 0}}$ 0.003 (0.042) 0.070 (0.039) 0.074 (0.053)
    ${\varphi _i}$ 0.020 (0.054) -0.121* (0.048) -0.043 (0.064)
    Conditional variance equation
    $\alpha _{i, 0}^*$ -0.116 (0.060) -0.032 (0.039) -0.094* (0.047)
    ${\alpha _i}$ 0.960* (0.021) 0.948* (0.020) 0.922* (0.051)
    ${\theta _i}$ -0.171* (0.042) -0.196* (0.037) -0.158* (0.064)
    ${\gamma _i}$ 0.127 (0.069) 0.013 (0.045) 0.111 (0.058)
    Conditional density parameters
    ${\nu _i}$ 16.189 (13.063) 8.957 (5.524)
    ${\lambda _i}$ -0.206* (0.087)
    Asymmetry effect for market i
    ${\delta _i} = {\theta _i}/{\gamma _i}$ -1.35 < 0 -15.08 < 0 -1.42 < 0
    Half–life (HL) 16.98 12.98 8.54
    Log–likelihood -391.26 -527.81 -382.62
    LB(20) 16.96 [0.66] 17.98 [0.59] 14.19 [0.82]
    LB2(20) 8.01 [0.99] 14.78 [0.79] 13.95 [0.83]
    Source: Authors' calculations.
    Notes: See Table 2 for explanations.
     | Show Table
    DownLoad: CSV
    Table 4. Results from the AR (1)–EGARCH (1, 1) models of three stock indexes: FTSE100, CAC40 and DAX, in the GFC period.
    London (i=1) Paris (i=2) Frankfurt (i=3)
    GFC period 31.10.2007–27.02.2009 331 daily observations 31.05.2007–27.02.2009 439 daily observations 28.12.2007–27.02.2009 292 daily observations
    The distribution for the innovations (the best fitted model) normal normal skewed t
    Conditional mean equation
    ${\varphi _{i, 0}}$ -0.233* (0.094) -0.199* (0.000) -0.224* (0.000)
    ${\varphi _i}$ -0.119* (0.052) -0.087* (0.000) -0.030* (0.000)
    Conditional variance equation
    $\alpha _{i, 0}^*$ -0.059 (0.034) -0.086* (0.033) -0.030 (0.037)
    ${\alpha _i}$ 0.970* (0.013) 0.971* (0.010) 0.972* (0.010)
    ${\theta _i}$ -0.136* (0.032) -0.193* (0.040) -0.177* (0.033)
    ${\gamma _i}$ 0.128* (0.045) 0.151* (0.038) 0.085* (0.041)
    Conditional density parameters
    ${\nu _i}$ 11.092 (7.300)
    ${\lambda _i}$ -0.061 (0.077)
    Asymmetry effect for market i
    ${\delta _i} = {\theta _i}/{\gamma _i}$ -1.06 < 0 -1.28 < 0 -2.08 < 0
    Half–life (HL) 22.76 23.55 24.40
    Log–likelihood -667.62 -853.18 -599.32
    LB(20) 17.01 [0.65] 17.00 [0.65] 8.91 [0.98]
    LB2(20) 21.33 [0.38] 33.59 [0.03] 35.59 [0.02]
    Source: Authors' calculations.
    Notes: See Table 2 for explanations.
     | Show Table
    DownLoad: CSV
    Table 5. Results from the AR (1)–EGARCH (1, 1) models of three stock indexes: FTSE100, CAC40, and DAX, in the post-GFC period.
    London (i=1) Paris (i=2) Frankfurt (i=3)
    Post-GFC period 2.03.2009–28.06.2010 331 daily observations 2.03.2007–26.11.2010 439 daily observations 2.03.2009–30.04.2010 292 daily observations
    The distribution for the innovations (the best fitted model) normal normal normal
    Conditional mean equation
    ${\varphi _{i, 0}}$ 0.070 (0.061) 0.030 (0.060) 0.152 (0.089)
    ${\varphi _i}$ -0.020 (0.062) -0.060 (0.049) -0.060 (0.071)
    Conditional variance equation
    $\alpha _{i, 0}^*$ -0.135* (0.034) -0.093* (0.038) -0.027 (0.076)
    ${\alpha _i}$ 0.958* (0.022) 0.936* (0.028) 0.999* (0.006)
    ${\theta _i}$ -0.144* (0.056) -0.185* (0.059) 0.019 (0.045)
    ${\gamma _i}$ 0.190* (0.044) 0.182* (0.044) 0.030 (0.099)
    Asymmetry effect for market i
    ${\delta _i} = {\theta _i}/{\gamma _i}$ -0.76 < 0 -1.02 < 0 0.63 > 0
    Half–life (HL) 16.15 10.48 692.80
    Log–likelihood -531.96 -779.07 -523.18
    LB(20) 22.06 [0.34] 15.53 [0.75] 14.41 [0.81]
    LB2(20) 30.57 [0.06] 40.06 [0.005] 30.64 [0.06]
    Source: Authors' calculations.
    Notes: See Table 2 for explanations.
     | Show Table
    DownLoad: CSV

    4. Conclusion

    The aim of this study was to explore the asymmetric impact of innovations on volatility on the major developed European stock markets in the UK, France and Germany, by using the EGARCH based approach. The sample covered the period from January 2003 to December 2016, and it included the 2007 U.S. subprime crisis. The robustness analysis of empirical results was provided with respect to the whole sample and three adjacent subsamples, each of equal size: 1) the pre-GFC, 2) the GFC, and 3) the post-GFC periods. Our research confirmed the pronounced asymmetric impact of innovations on volatility in the case of all analyzed stock markets. We conclude that negative innovations have a higher impact on volatility than positive innovations. Our findings are rather consistent with the literature and suggest that the investigated stock markets are more sensitive to 'bad' than 'good' news, regardless of the subsample choice. From an investor's point of view it is important that these findings are also in accordance with the investor's intuition. Moreover, the results are essentially not surprising if we take into account that the major European financial markets are strongly connected 'every day', not only during financial crises. Due to the importance of the problem, a possible direction for further research would be an investigation of asymmetry effects in the case of the European stock markets in terms of other asymmetric GARCH-type models (Engle, 2000; Bauwens et al., 2006).


    Acknowledgments

    The contribution of the first named author was supported by a grant S/WI/1/2014 from Bialystok University of Technology and founded from the resources for research by Ministry of Science and Higher Education.


    Conflict of Interest

    All authors declare no conflict of interest.


    [1] Hodder SL, Justman J, Haley DF, et al. (2010) Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr 55 Suppl 2: S69–S73.
    [2] Shattock RJ, Rosenberg Z (2012) Microbicides: Topical prevention against HIV. Cold Spring Harb Perspect Med 2: a007385.
    [3] UNAIDS. Available from: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
    [4] Swanson MD, Winter HC, Goldstein IJ, et al. (2010) A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem 285: 8646–8655. doi: 10.1074/jbc.M109.034926
    [5] Murphy EM, Greene ME, Mihailovic A, et al. (2006) Was the "ABC" approach (abstinence, being faithful, using condoms) responsible for Uganda's decline in HIV? PLoS Med 3: 1–5.
    [6] Cohen SA. Available from: https://www.guttmacher.org/gpr/2004/11/promoting-b-abc-its-value-and-limitations-fostering-reproductive-health.
    [7] Sovran S (2013) Understanding culture and HIV/AIDS in sub-Saharan Africa. Sahara J 10: 32–41.
    [8] Reniers G, Watkins S (2010) Polygyny and the spread of HIV in sub-Saharan Africa: A case of benign concurrency. Aids 24: 299–307. doi: 10.1097/QAD.0b013e328333af03
    [9] Helweglarsen M, Collins BE (1994) The UCLA Multidimensional Condom Attitudes Scale: Documenting the complex determinants of condom use in college students. Health Psychol 13: 224–237. doi: 10.1037/0278-6133.13.3.224
    [10] UNAIDS. Available from: http://www.unaids.org/globalreport/Global_report.htm.
    [11] Qian K, Morris-Natschke SL, Lee KH (2009) HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 29: 369–393. doi: 10.1002/med.20138
    [12] Fohona S, Coulibaly BBC (2017) Current status of lectin-based cancer diagnosis and therapy. AIMS Mol Sci 4: 1–27.
    [13] Hansen TK, Gall MA, Tarnow L, et al. (2007) Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 166: 2007–2013.
    [14] Guan LZ, Tong Q, Xu J (2015) Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS One 10: 1–10.
    [15] Losin IE, Shakhnovich RM, Zykov KA, et al. (2014) Cardiovascular diseases and mannose-binding lectin. Kardiologiia 54: 64–70.
    [16] Kelsall A, Fitzgerald AJ, Howard CV, et al. (2002) Dietary lectins can stimulate pancreatic growth in the rat. Int J Exp Pathol 83: 203–208. doi: 10.1046/j.1365-2613.2002.00230.x
    [17] Hoyem PH, Bruun JM, Pedersen SB, et al. (2012) The effect of weight loss on serum mannose-binding lectin levels. Clin Dev Immunol 2012: 1–5.
    [18] Akkouh O, Ng TB, Singh SS, et al. (2015) Lectins with anti-HIV activity: A review. Molecules 20: 648–668. doi: 10.3390/molecules20010648
    [19] Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582–608. doi: 10.1016/j.jmb.2011.04.042
    [20] Balzarini J, Van LK, Hatse S, et al. (2004) Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 78: 10617–10627. doi: 10.1128/JVI.78.19.10617-10627.2004
    [21] Huskens D, Van LK, Vermeire K, et al. (2007) Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 360: 294–304. doi: 10.1016/j.virol.2006.10.027
    [22] Blumenthal R, Durell S, Viard M (2012) HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem 287: 40841–40849. doi: 10.1074/jbc.R112.406272
    [23] Wilen CB, Tilton JC, Doms RW (2012) HIV: Cell binding and entry. Cold Spring Harb Perspect Med 2: 1–13
    [24] Ratner L, Haseltine W, Patarca R, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277–284. doi: 10.1038/313277a0
    [25] Allan JS, Coligan JE, Barin F, et al. (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091–1094. doi: 10.1126/science.2986290
    [26] Montagnier L, Clavel F, Krust B, et al. (1985) Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology 144: 283–289. doi: 10.1016/0042-6822(85)90326-5
    [27] Wainhobson S, Sonigo P, Danos O, Cole S, et al. (1985) Nucleotide sequence of the AIDS virus, LAV. Cell 40: 9–17. doi: 10.1016/0092-8674(85)90303-4
    [28] Mizuochi T, Spellman MW, Larkin M, et al. (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: 599–603. doi: 10.1042/bj2540599
    [29] Mizuochi T, Spellman MW, Larkin M, et al. (1988) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biomed Chromatogr 2: 260–270.
    [30] Mizuochi T, Matthews TJ, Kato M, et al. (1990) Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265: 8519–8524.
    [31] Geyer H, Holschbach C, Hunsmann G, et al. (1988) Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 263: 11760–11767.
    [32] Go EP, Hewawasam G, Liao HX, et al. (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85: 8270–8284. doi: 10.1128/JVI.05053-11
    [33] Bonomelli C, Doores KJ, Dunlop DC, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: 1–7.
    [34] Go EP, Herschhorn A, Gu C, et al. (2015) Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. J Virol 89: 8245–8257. doi: 10.1128/JVI.00628-15
    [35] Raska M, Takahashi K, Czernekova L, et al. (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285: 20860–20869. doi: 10.1074/jbc.M109.085472
    [36] Zhu X, Borchers C, Bienstock RJ, et al. (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194–11204. doi: 10.1021/bi000432m
    [37] Doores KJ, Bonomelli C, Harvey DJ, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: 13800–13805. doi: 10.1073/pnas.1006498107
    [38] Behrens AJ, Harvey DJ, Milne E, et al. (2017) Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. J Virol 91: 1–16.
    [39] Sok D, Doores KJ, Briney B, et al. (2014) Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6: 1–15.
    [40] Pritchard LK, Spencer DI, Royle L, et al. (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6: 1–11.
    [41] Coss KP, Vasiljevic S, Pritchard LK, et al. (2016) HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. J Virol 90: 11132–11144. doi: 10.1128/JVI.01542-16
    [42] Raska M, Novak J (2010) Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection. Arch Immunol Ther Exp 58: 191–208. doi: 10.1007/s00005-010-0072-3
    [43] Wang SK, Liang PH, Astronomo RD, et al. (2008) Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A 105: 3690–3695. doi: 10.1073/pnas.0712326105
    [44] Balzarini J (2005) Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 5: 726–731. doi: 10.1016/S1473-3099(05)70271-1
    [45] Koch M, Pancera M, Kwong PD, et al. (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313: 387–400. doi: 10.1016/S0042-6822(03)00294-0
    [46] Rathore U, Saha P, Kesavardhana S, et al. (2017) Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. J Biol Chem 24: 10197–10219.
    [47] Sanders RW, Anken EV, Nabatov AA, et al. (2008) The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 5: 1–15. doi: 10.1186/1742-4690-5-1
    [48] Montefiori DC, Jr RW, Mitchell WM (1988) Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 85: 9248–9252. doi: 10.1073/pnas.85.23.9248
    [49] Francois KO, Balzarini J (2011) The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem 286: 42900–42910. doi: 10.1074/jbc.M111.274456
    [50] Mathys L, Francois KO, Quandte M, et al. (2014) Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One 9: 1–11.
    [51] Huang X, Jin W, Hu K, et al. (2012) Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423: 97–106. doi: 10.1016/j.virol.2011.11.023
    [52] Binley JM, Ban YE, Crooks ET, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84: 5637–5655. doi: 10.1128/JVI.00105-10
    [53] Li Y, Luo L, Rasool N, et al. (1993) Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 67: 584–588.
    [54] Li H, Jr CP, Tuen M, Visciano ML, et al. (2008) Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 180: 4011–4021. doi: 10.4049/jimmunol.180.6.4011
    [55] Behrens AJ, Vasiljevic S, Pritchard LK, et al. (2016) Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Rep 14: 2695–2706. doi: 10.1016/j.celrep.2016.02.058
    [56] Pritchard LK, Vasiljevic S, Ozorowski G, et al. (2015) Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Rep 11: 1604–1613. doi: 10.1016/j.celrep.2015.05.017
    [57] Steckbeck JD, Craigo JK, Barnes CO, et al. (2011) Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: Implications for functions in viral replication. J Biol Chem 286: 27156–27166. doi: 10.1074/jbc.M111.258855
    [58] Dimonte S, Mercurio F, Svicher V, et al. (2011) Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor usage. Retrovirology 8: 1–11. doi: 10.1186/1742-4690-8-1
    [59] Perrin C, Fenouillet E, Jones IM (1998) Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein. Virology 242: 338–345. doi: 10.1006/viro.1997.9016
    [60] Johnson WE, Sauvron JM, Desrosiers RC (2001) Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication. J Virol 75: 11426–11436. doi: 10.1128/JVI.75.23.11426-11436.2001
    [61] Fenouillet E (1993) La N-glycosylation du VIH: Du modèle expérimental à l'application thérapeutique. J Libbery Eurotext Montrouge 9: 901–906.
    [62] Fenouillet E, Jones IM (1995) The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J Gen Virol 76: 1509–1514. doi: 10.1099/0022-1317-76-6-1509
    [63] Lee WR, Yu XF, Syu WJ, et al. (1992) Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J Virol 66: 1799–1803.
    [64] Ma BJ, Alam SM, Go EP, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: 1–16.
    [65] Wang LX, Song H, Liu S, et al. (2005) Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: Effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. Chembiochem 6: 1068–1074. doi: 10.1002/cbic.200400440
    [66] Balzarini J, Van LK, Hatse S, et al. (2005) Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: A new therapeutic concept to hit the achilles heel of HIV. J Biol Chem 280: 41005–41014. doi: 10.1074/jbc.M508801200
    [67] Van AE, Sanders RW, Liscaljet IM, et al. (2008) Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. Mol Biol Cell 19: 4298–4309. doi: 10.1091/mbc.E07-12-1282
    [68] Mathys L, Balzarini J (2014) The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents. Retrovirology 11: 1–18. doi: 10.1186/1742-4690-11-1
    [69] Fenouillet E, Jones I, Powell B, et al. (1993) Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol 67: 150–160.
    [70] Yuste E, Bixby J, Lifson J, et al. (2008) Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J Virol 82: 12472–12486. doi: 10.1128/JVI.01382-08
    [71] Tanaka H, Chiba H, Inokoshi J, et al. (2009) Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 106: 15633–15638. doi: 10.1073/pnas.0907572106
    [72] Hoorelbeke B, Huskens D, Ferir G, et al. (2010) Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 54: 3287–32301. doi: 10.1128/AAC.00254-10
    [73] Zhang F, Hoque MM, Jiang J, et al. (2014) The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120. Chembiochem 15: 2766–2773. doi: 10.1002/cbic.201402352
    [74] Bewley CA, Gustafson KR, Boyd MR, et al. (1998) Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol 5: 571–578. doi: 10.1038/828
    [75] Barrientos LG, Louis JM, Ratner DM, et al. (2003) Solution structure of a circular-permuted variant of the potent HIV-inactivating protein cyanovirin-N: Structural basis for protein stability and oligosaccharide interaction. J Mol Biol 325: 211–223. doi: 10.1016/S0022-2836(02)01205-6
    [76] Esser MT, Mori T, Mondor I, et al. (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 73: 4360–4371.
    [77] Alexandre KB, Gray ES, Mufhandu H, et al. (2012) The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 423: 175–186. doi: 10.1016/j.virol.2011.12.001
    [78] Buffa V, Stieh D, Mamhood N, et al. (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90: 234–243. doi: 10.1099/vir.0.004358-0
    [79] Boyd MR, Gustafson KR, Mcmahon JB, et al. (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Agents Chemother 41: 1521–1530.
    [80] Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368: 145–154. doi: 10.1016/j.virol.2007.06.029
    [81] Keeffe JR, Gnanapragasam PN, Gillespie SK, et al. (2011) Designed oligomers of cyanovirin-N show enhanced HIV neutralization. Proc Natl Acad Sci U S A 108: 14079–14084. doi: 10.1073/pnas.1108777108
    [82] Dey B, Lerner DL, Lusso P, et al. (2000) Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74: 4562–4569. doi: 10.1128/JVI.74.10.4562-4569.2000
    [83] Férir G, Huskens D, Noppen S, et al. (2014) Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family. J Antimicrob Chemother 69: 2746–2758. doi: 10.1093/jac/dku220
    [84] Koharudin LM, Gronenborn AM (2011) Structural basis of the anti-HIV activity of the cyanobacterial Oscillatoria Agardhii agglutinin. Structure 19: 1170–1181. doi: 10.1016/j.str.2011.05.010
    [85] Koharudin LM, Furey W, Gronenborn AM (2011) Novel fold and carbohydrate specificity of the potent anti-HIV cyanobacterial lectin from Oscillatoria agardhii. J Biol Chem 286: 1588–1597. doi: 10.1074/jbc.M110.173278
    [86] Carneiro MG, Koharudin LM, Ban D, et al. (2015) Sampling of Glycan-Bound Conformers by the Anti-HIV Lectin Oscillatoria agardhii agglutinin in the Absence of Sugar. Angew Chem 54: 6462–6465. doi: 10.1002/anie.201500213
    [87] Bokesch HR, O'Keefe BR, Mckee TC, et al. (2003) A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42: 2578–2584. doi: 10.1021/bi0205698
    [88] Adams EW, Ratner DM, Bokesch HR, et al. (2004) Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 11: 875–881. doi: 10.1016/j.chembiol.2004.04.010
    [89] Mcfeeters RL, Xiong C, O'Keefe BR, et al. (2007) The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors. J Mol Biol 369: 451–461. doi: 10.1016/j.jmb.2007.03.030
    [90] Alexandre KB, Gray ES, Lambson BE, et al. (2010) Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402: 187–196. doi: 10.1016/j.virol.2010.03.021
    [91] Williams DC, Lee JY, Cai M, et al. (2005) Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: Structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside. J Biol Chem 280: 29269–29276. doi: 10.1074/jbc.M504642200
    [92] Ziółkowska NE, Wlodawer A (2006) Structural studies of algal lectins with anti-HIV activity. Acta Biochim Pol 53: 617–626.
    [93] Shahzadulhussan S, Gustchina E, Ghirlando R, et al. (2011) Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1–2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem 286: 20788–20796. doi: 10.1074/jbc.M111.232678
    [94] Huskens D, Ferir G, Vermeire K, et al. (2010) Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 285: 24845–24854. doi: 10.1074/jbc.M110.128546
    [95] López S, Armandugon M, Bastida J, et al. (2003) Anti-human immunodeficiency virus type 1 (HIV-1) activity of lectins from Narcissus species. Planta Med 69: 109–112. doi: 10.1055/s-2003-37715
    [96] Müller WEG, Forrest JMS, Chang SH, et al. (1991) Narcissus and Gerardia lectins: Tools for the development of a vaccine against AIDS and a new ELISA to quantify HIV-gp 120. Lectins Cancer 1991: 27–40.
    [97] Charan RD, Munro MH, O'Keefe BR, et al. (2000) Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii(1). J Nat Prod 63: 1170–1174. doi: 10.1021/np000039h
    [98] Coulibaly FS, Youan BB (2014) Concanavalin A-polysaccharides binding affinity analysis using a quartz crystal microbalance. Biosens Bioelectron 59: 404–411. doi: 10.1016/j.bios.2014.03.040
    [99] Bhattacharyya L, Brewer CF (1989) Interactions of concanavalin A with asparagine-linked glycopeptides. Structure/activity relationships of the binding and precipitation of oligomannose and bisected hybrid-type glycopeptides with concanavalin A. Eur J Biochem 178: 721–726.
    [100] Witvrouw M, Fikkert V, Hantson A, et al. (2005) Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 79: 7777–7784. doi: 10.1128/JVI.79.12.7777-7784.2005
    [101] Hansen JE, Nielsen CM, Nielsen C, et al. (1989) Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. Aids 3: 635–641. doi: 10.1097/00002030-198910000-00003
    [102] Matsui T, Kobayashi S, Yoshida O, et al. (1990) Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus. Med Microbiol Immunol 179: 225–235.
    [103] Pashov A, Macleod S, Saha R, et al. (2005) Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology 15: 994–1001. doi: 10.1093/glycob/cwi083
    [104] Swanson MD, Boudreaux DM, Salmon L, et al. (2015) Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell 163: 746–758. doi: 10.1016/j.cell.2015.09.056
    [105] Alexandre KB, Gray ES, Pantophlet R, et al. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol 85: 9039–9050. doi: 10.1128/JVI.02675-10
    [106] Mori T, O'Keefe BR, Bringans S, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280: 9345–9353. doi: 10.1074/jbc.M411122200
    [107] Emau P, Tian B, O'Keefe BR, et al. (2007) Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 36: 244–253. doi: 10.1111/j.1600-0684.2007.00242.x
    [108] Moulaei T, Alexandre KB, Shenoy SR, et al. (2015) Griffithsin tandemers: Flexible and potent lectin inhibitors of the human immunodeficiency virus. Retrovirology 12: 1–14. doi: 10.1186/s12977-014-0129-1
    [109] Zhou X, Liu J, Yang B, et al. (2013) Marine natural products with anti-HIV activities in the last decade. Curr Med Chem 20: 953–973.
    [110] Wang JH, Kong J, Li W, et al. (2006) A beta-galactose-specific lectin isolated from the marine worm Chaetopterus variopedatus possesses anti-HIV-1 activity. Comp Biochem Physiol C Toxicol Pharmacol 142: 111–117. doi: 10.1016/j.cbpc.2005.10.019
    [111] Bulgheresi S, Schabussova I, Chen T, et al. (2006) A new C-type lectin similar to the human immunoreceptor DC-SIGN mediates symbiont acquisition by a marine nematode. Appl Environ Microbiol 72: 2950–2956. doi: 10.1128/AEM.72.4.2950-2956.2006
    [112] Nabatov AA, Jong MAWPD, Witte LD, et al. (2008) C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells. Virology 378: 323–328. doi: 10.1016/j.virol.2008.05.025
    [113] Molchanova V, Chikalovets I, Chernikov O, et al. (2007) A new lectin from the sea worm Serpula vermicularis: Isolation, characterization and anti-HIV activity. Comp Biochem Physiol C Toxicol Pharmacol 145: 184–193. doi: 10.1016/j.cbpc.2006.11.012
    [114] Vo TS, Kim SK (2010) Potential anti-HIV agents from marine resources: An overview. Mar Drugs 8: 2871–2892. doi: 10.3390/md8122871
    [115] Mahalingam A, Geonnotti AR, Balzarini J, et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharmaceutics 8: 2465–2475. doi: 10.1021/mp2002957
    [116] Berube M, Dowlut M, Hall DG (2008) Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: Structure and selectivity of complex formation. J Org Chem 73: 6471–6479. doi: 10.1021/jo800788s
    [117] Trippier PC, Mcguigan C, Balzarini J (2010) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: Monophenylboronic acids. Antivir Chem Chemother 20: 249–257.
    [118] Trippier PC, Balzarini J, Mcguigan C (2011) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: Bisphenylboronic acids. Antivir Chem Chemother 21: 129–142.
    [119] Khan JM, Qadeer A, Ahmad E, et al. (2013) Monomeric banana lectin at acidic pH overrules conformational stability of its native dimeric form. PLoS One 8: 1–12.
    [120] Suzuki K, Ohbayashi N, Jiang J, et al. (2012) Crystallographic study of the interaction of the anti-HIV lectin actinohivin with the alpha(1-2)mannobiose moiety of gp120 HMTG. Acta Crystallogr Sect F Struct Biol Cryst Commun 68: 1060–1063. doi: 10.1107/S1744309112031077
    [121] Tevibénissan C, Bélec L, Lévy M, et al. (1997) In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 4: 367–374.
    [122] Ballerstadt R, Evans C, Mcnichols R, et al. (2006) Concanavalin A for in vivo glucose sensing: A biotoxicity review. Biosens Bioelectron 22: 275–284. doi: 10.1016/j.bios.2006.01.008
    [123] Krauss S, Buttgereit F, Brand MD (1999) Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. Biochim Biophys Acta 1412: 129–138. doi: 10.1016/S0005-2728(99)00058-4
    [124] Balzarini J, Laethem KV, Peumans WJ, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80: 8411–8421. doi: 10.1128/JVI.00369-06
    [125] Gavrovicjankulovic M, Poulsen K, Brckalo T, et al. (2008) A novel recombinantly produced banana lectin isoform is a valuable tool for glycoproteomics and a potent modulator of the proliferation response in CD3+, CD4+, and CD8+ populations of human PBMCs. Int J Biochem Cell Biol 40: 929–941. doi: 10.1016/j.biocel.2007.10.033
    [126] Mahalingam A, Geonnotti AR, Balzarini J, et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm 8: 2465–2475. doi: 10.1021/mp2002957
    [127] Lam SK, Ng TB (2011) Lectins: Production and practical applications. Appl Microbiol Biotechnol 89: 45–55. doi: 10.1007/s00253-010-2892-9
    [128] Scanlan CN, Offer J, Zitzmann N, et al. (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038–1045. doi: 10.1038/nature05818
    [129] Gupta A, Gupta RK, Gupta GS (2009) Targeting cells for drug and gene delivery: Emerging applications of mannans and mannan binding lectins. J Sci Ind Res 68: 465–483.
    [130] Ghazarian H, Idoni B, Oppenheimer SB (2011) A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 113: 236–247. doi: 10.1016/j.acthis.2010.02.004
    [131] Toda S, Ishii N, Okada E, et al. (1997) HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 92: 111–117. doi: 10.1046/j.1365-2567.1997.00307.x
    [132] Zelensky AN, Gready JE (2005) The C-type lectin-like domain superfamily. FEBS J 272: 6179–6217. doi: 10.1111/j.1742-4658.2005.05031.x
    [133] Cui Z, Hsu CH, Mumper RJ (2003) Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm 29: 689–700. doi: 10.1081/DDC-120021318
    [134] Espuelas S, Thumann C, Heurtault B, et al. (2008) Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjugate Chem 19: 2385–2393. doi: 10.1021/bc8002524
    [135] Zhang Q, Su L, Collins J, et al. (2014) Dendritic cell lectin-targeting sentinel-like unimolecular glycoconjugates to release an anti-HIV drug. J Am Chem Soc 136: 4325–4332. doi: 10.1021/ja4131565
    [136] Hong PWP, Flummerfelt KB, Parseval AD, et al. (2002) Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding. J Virol 76: 12855–12865. doi: 10.1128/JVI.76.24.12855-12865.2002
    [137] Cruz LJ, Tacken PJ, Fokkink R, et al. (2010) Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Controlled Release 144: 118–126. doi: 10.1016/j.jconrel.2010.02.013
    [138] Ingale J, Stano A, Guenaga J, et al. (2016) High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15: 1986–1999. doi: 10.1016/j.celrep.2016.04.078
    [139] He L, Val ND, Morris CD, et al. (2016) Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun 7: 1–15.
    [140] Akashi M, Niikawa T, Serizawa T, et al. (1998) Capture of HIV-1 gp120 and virions by lectin-immobilized polystyrene nanospheres. Bioconjugate Chem 9: 50–53. doi: 10.1021/bc970045y
    [141] Hayakawa T, Kawamura M, Okamoto M, et al. (1998) Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: Potential approach towards prevention of viral transmission. J Med Virol 56: 327–331. doi: 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
    [142] Coulibaly FS, Ezoulin MJM, Purohit SS, et al. (2017) Layer-by-layer engineered microbicide drug delivery system targeting HIV-1 gp120: Physicochemical and biological properties. Mol Pharm 14: 3512–3527.
    [143] Takahashi K, Moyo P, Chigweshe L, et al. (2013) Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res 178: 495–501. doi: 10.1016/j.virusres.2013.10.001
    [144] Sato Y, Morimoto K, Kubo T, et al. (2015) Entry Inhibition of Influenza Viruses with High Mannose Binding Lectin ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral Hemagglutinin. Mar Drugs 13: 3454–3465. doi: 10.3390/md13063454
    [145] Kachko A, Loesgen S, Shahzad-Ul-Hussan S, et al. (2013) Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: Mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharmaceutics 10: 4590–4602. doi: 10.1021/mp400399b
    [146] Gadjeva M, Paludan SR, Thiel S, et al. (2004) Mannan-binding lectin modulates the response to HSV-2 infection. Clin Exp Immunol 138: 304–311. doi: 10.1111/j.1365-2249.2004.02616.x
    [147] Eisen S, Dzwonek A, Klein NJ (2008) Mannose-binding lectin in HIV infection. Future Virol 3: 225–233. doi: 10.2217/17460794.3.3.225
    [148] Ji X, Olinger GG, Aris S, et al. (2005) Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 86: 2535–2542. doi: 10.1099/vir.0.81199-0
    [149] Keyaerts E, Vijgen L, Pannecouque C, et al. (2007) Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 75: 179–187. doi: 10.1016/j.antiviral.2007.03.003
    [150] Hamel R, Dejarnac O, Wichit S, et al. (2015) Biology of Zika Virus Infection in Human Skin Cells. J Virol 89: 8880–8896. doi: 10.1128/JVI.00354-15
    [151] Clement F, Venkatesh YP (2010) Dietary garlic (Allium sativum) lectins, ASA I and ASA II, are highly stable and immunogenic. Int Immunopharmacol 10: 1161–1169. doi: 10.1016/j.intimp.2010.06.022
    [152] Lusvarghi S, Bewley CA (2016) Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 8: 1–18.
  • This article has been cited by:

    1. Venus Khim-Sen Liew, The effect of novel coronavirus pandemic on tourism share prices, 2020, ahead-of-print, 2055-5911, 10.1108/JTF-03-2020-0045
    2. Deby Fakhriyana, Kartika Fithriasari, 2019, 2194, 0094-243X, 020025, 10.1063/1.5139757
    3. Mesfer Mahdi Al Mesfer Al Ajmi, The Impact of the Covid-19 Pandemic on Boursa Kuwait Return Volatility, 2021, 9, 2347-4696, 473, 10.37391/IJBMR.090411
    4. Sinem ATICI USTALAR, Selim ŞANLISOY, COVID-19 Krizi’nin Türkiye ve G7 Ülkelerinin Borsa Oynaklıkları Üzerindeki Etkisi, 2021, 16, 1306-6730, 446, 10.17153/oguiibf.884895
    5. Bartłomiej Lisicki, The impact of the COVID-19 pandemic on the equity market risk measured by the beta coefficient, 2023, 68, 2543-8476, 1, 10.5604/01.3001.0016.2360
    6. Elena Villar-Rubio, María-Dolores Huete-Morales, Federico Galán-Valdivieso, Using EGARCH models to predict volatility in unconsolidated financial markets: the case of European carbon allowances, 2023, 2190-6483, 10.1007/s13412-023-00838-5
    7. Muhammad Mohsin, Li Naiwen, Muhammad Zia-UR-Rehman, Sobia Naseem, Sajjad Ahmad Baig, The volatility of bank stock prices and macroeconomic fundamentals in the Pakistani context: an application of GARCH and EGARCH models, 2020, 11, 2353-1827, 609, 10.24136/oc.2020.025
    8. Yuriy Bibik, Forecasting in Stock Markets Using the Formalism of Statistical Mechanics, 2023, 22, 2713-3206, 1499, 10.15622/ia.22.6.9
    9. Bartłomiej Lisicki, Differentiation of Beta Coefficients during COVID-19 Pandemic – the Example of Stocks of the Largest Companies Listed on the Warsaw Stock Exchange, 2023, 2545-3238, 11, 10.15678/ZNUEK.2022.0998.0401
    10. Sungjae Yoon, Hiroshi Takahashi, Intraday Trading Dynamics of Characteristics and Sentiment Tendencies of Past News in the Tokyo Stock Exchange Market, 2025, 0927-7099, 10.1007/s10614-024-10768-1
  • Reader Comments
  • © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(7474) PDF downloads(2120) Cited by(6)

Article outline

Figures and Tables

Figures(2)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog